BiotechTube

fospropofol + fospropofol + fospropofol + fospropofol

Pre-clinicalWithdrawn
0 watching 0 views this week💤 Quiet
23
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Impaired Airway Clearance

Conditions

Impaired Airway Clearance

Trial Timeline

Feb 1, 2011 → Apr 1, 2011

NCT ID
NCT01289483

About fospropofol + fospropofol + fospropofol + fospropofol

fospropofol + fospropofol + fospropofol + fospropofol is a pre-clinical stage product being developed by Eisai for Impaired Airway Clearance. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT01289483. Target conditions include Impaired Airway Clearance.

Hype Score Breakdown

Clinical
5
Activity
2
Company
10
Novelty
2
Community
1

Clinical Trials (1)

NCT IDPhaseStatus
NCT01289483Pre-clinicalWithdrawn

Competing Products

19 competing products in Impaired Airway Clearance

See all competitors
ProductCompanyStageHype Score
Aspirin + Alpha lipoic acid + Olmesartan + PlaceboDaiichi SankyoPre-clinical
23
ASP8825Astellas PharmaPhase 1
33
ASP015KAstellas PharmaPhase 1
33
ASP015KAstellas PharmaPhase 1
33
GilteritinibAstellas PharmaPhase 1
33
Exenatide + MetforminEli LillyApproved
85
Apatinib MesylateJiangsu Hengrui MedicinePhase 1
33
balcinrenone/dapagliflozin 15 mg/10 mg and matching placebo for dapagliflozin 10 mg + balcinrenone/dapagliflozin 40 mg/10 mg and matching placebo for dapagliflozin 10 mg + dapagliflozin 10 mg and matching placebo for balcinrenone/dapagliflozinAstraZenecaPhase 3
77
Tetanus & Diphtheria booster vaccine (Td) + TwinrixTM [Hepatitis A Inactivated & Hepatitis B (Recombinant) Vaccine] + Dukoral® Traveler's Diarrhea Vaccine (WC/rBS)MerckPre-clinical
23
ASA404NovartisPhase 1
33
MAS825 + Standard of Care (SoC)NovartisPhase 2
52
DFV890 + Standard of Care (SoC)NovartisPhase 2
52
Immediate switch to TDF/FTC/RPV + Switch to TDF/FTC/RPV after 24 weeksGilead SciencesApproved
84
Gabapentin + Gabapentin + Gabapentin + GabapentinPfizerApproved
84
Ramipril + RosiglitazonePfizerPhase 3
76
HSK7653 10mg Q2W + HSK7653 25mg Q2W + PlaceboHaisco Pharmaceutical GroupPhase 2
49
NBI-98854 50 mg capsuleNeurocrine BiosciencesPhase 1
30
BIS-001ERSupernus PharmaceuticalsPhase 1/2
36
GFT505 80mg + PlaceboGenfitPhase 2
44

Other Products from Eisai

MecobalaminApproved
85
MonteplaseApproved
85
E2020 + PlaceboApproved
85
Palonosetron 0.075 mg IV + Dexamethasone 10 mg IV + Promethazine 25 mg IVApproved
85
DonepezilApproved
85